Evidence map›Paper›PMID 39003524›Full record

ArticleAIDS research and human retroviruses2024

Improving Recruitment and Retention of Transgender Women in HIV Prevention Trials: Strategies to Make Trial Participation More Congruent with the Needs of Transgender Women.

Doyel Das, Javier Lopez-Rios, Stacey A McKenna, Jonathan Porter, Curtis Dolezal, Pilar Giffenig, Michael Patrick Vaughn, Elena Abascal, Jasmine Michelle Lopez, Christine Tagliaferri Rael

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and human retroviruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Doyel DasHIV Center for Clinical and Behavioral Studies, Columbia University, New York, New York, USA.
Javier Lopez-RiosDepartment of Community Health and Prevention, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania, USA.
Stacey A McKennaConsultant at Stacey McKenna, LLC, Fort Collins, Colorado, USA.
Jonathan PorterHIV Center for Clinical and Behavioral Studies, Columbia University, New York, New York, USA.
Curtis DolezalHIV Center for Clinical and Behavioral Studies, Columbia University, New York, New York, USA.
Pilar GiffenigHIV Center for Clinical and Behavioral Studies, Columbia University, New York, New York, USA.
Michael Patrick VaughnHIV Center for Clinical and Behavioral Studies, Columbia University, New York, New York, USA.
Elena AbascalColumbia University School of Nursing, New York, New York, USA.
Jasmine Michelle LopezHIV Center for Clinical and Behavioral Studies, Columbia University, New York, New York, USA.
Christine Tagliaferri RaelAnschutz Medical Campus, University of Colorado College of Nursing, Aurora CO, USA.ORCID 0000-0002-6303-3809

Funding

The Statistics, Data Science, and Data Management (SDM) CoreP30MH043520 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI MILTON L WAINBERG · 2003 to 2026
$48.2M
INSPIRE : Interdisciplinary Social and Behavioral Science Prevention and Intervention REsearch in HIVT32MH019139 · NIMH · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Claude Ann Mellins, Jae M. Sevelius · 1989 to 2026
$10.8M
Supplement: Developing Tailored Delivery and Adherence Interventions for use of Long-Acting Biomedical HIV Prevention Strategies by Transgender WomenK01MH115785 · NIMH · UNIVERSITY OF COLORADO DENVER · PI RAEL, CHRISTINE TAGLIAFERRI · 2018 to 2022
$767k
NIMH NIH HHS K01 MH115785NIMH NIH HHS P30 MH043520NIMH NIH HHS T32 MH019139
6 · The paper itself

Abstract

Transgender women are disproportionately burdened by HIV. Though there is a substantial body of research exploring barriers and facilitators of HIV prevention among transgender women, many barriers remain unaddressed. This study identifies strategies to make HIV prevention trials more congruent with transgender women's preferences and needs to boost trial participation and ultimately enhance initiation and uptake of pre-exposure prophylaxis (PrEP). We conducted in-depth interviews with 15 sexually active, HIV-negative transgender women in New York City to understand: (1) preferences concerning long-acting injectable cabotegravir for PrEP and (2) ideas on how to make HIV prevention trial environments more comfortable. We identified five themes related to increasing transgender women's appeal to trials: (1) creating a more inclusive/welcoming environment, (2) providing compensation that is responsive to transgender women and community needs, (3) centering transgender women in recruitment and informational materials, (4) training study staff on gender-affirming practices, and (5) hiring transgender people as study staff. Participants wanted to see more gender diversity, representation, correct pronouns, gender-affirming practices, and compensation or reimbursements. Together, these practices may improve recruitment and retention of transgender women in HIV prevention trials.

Indexed as

HIV InfectionsPatient SelectionPre-Exposure ProphylaxisTransgender PersonsAdultAnti-HIV AgentsClinical Trials as TopicDiketopiperazinesFemaleHumansInterviews as TopicMaleMiddle AgedNew York CityPyridonesYoung AdultAnti-HIV AgentscabotegravirDiketopiperazinesPyridonesdisparities in HIVHIVHIV preventionPrEP

Identifiers

PMID39003524
PMCPMC11693950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.